Chapter

9. Lyrfigtu for FGFR2-Positive Bile Duct Cancer

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

1. Lyrfigtu Approval

   "Lyrfigtu (lirafugratinib), a once-daily pill, is for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement. Tumors shrank in 46% of patients, and responses lasted a median of 11

2. Testing Effects

   "What it means for you: Only tumor testing can find an FGFR2 change, so ask whether your bile duct cancer has been tested. Side effects to know: nail changes, hand-foot skin reactions and mouth sores